CN102657876B - 免疫性习惯性流产的药物治疗及检测方法 - Google Patents
免疫性习惯性流产的药物治疗及检测方法 Download PDFInfo
- Publication number
- CN102657876B CN102657876B CN201210108746.5A CN201210108746A CN102657876B CN 102657876 B CN102657876 B CN 102657876B CN 201210108746 A CN201210108746 A CN 201210108746A CN 102657876 B CN102657876 B CN 102657876B
- Authority
- CN
- China
- Prior art keywords
- rsa
- chromosomes
- treatment
- abortion
- spontaneous abortion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000000995 spontaneous abortion Diseases 0.000 title claims abstract description 43
- 206010000234 Abortion spontaneous Diseases 0.000 title claims abstract description 42
- 230000000306 recurrent effect Effects 0.000 title claims abstract description 31
- 238000011282 treatment Methods 0.000 title claims description 45
- 239000003814 drug Substances 0.000 title claims description 19
- 238000000034 method Methods 0.000 title abstract description 35
- 230000001900 immune effect Effects 0.000 title abstract description 6
- 229940079593 drug Drugs 0.000 title description 7
- 238000012544 monitoring process Methods 0.000 title 1
- 210000000349 chromosome Anatomy 0.000 claims abstract description 62
- 230000003460 anti-nuclear Effects 0.000 claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 30
- 102000016359 Fibronectins Human genes 0.000 claims abstract description 30
- 239000012634 fragment Substances 0.000 claims abstract description 22
- 239000000463 material Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000000392 somatic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 13
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000036039 immunity Effects 0.000 description 30
- 230000035935 pregnancy Effects 0.000 description 28
- 206010000210 abortion Diseases 0.000 description 23
- 231100000176 abortion Toxicity 0.000 description 23
- 210000004698 lymphocyte Anatomy 0.000 description 22
- 238000002560 therapeutic procedure Methods 0.000 description 22
- 210000001161 mammalian embryo Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 210000005259 peripheral blood Anatomy 0.000 description 11
- 239000011886 peripheral blood Substances 0.000 description 11
- 210000000251 trophoblastic cell Anatomy 0.000 description 11
- 230000003053 immunization Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 208000015994 miscarriage Diseases 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 238000009169 immunotherapy Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000003754 fetus Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 210000003785 decidua Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000000280 densification Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003429 anti-cardiolipin effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000004252 chorionic villi Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000005058 diapause Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229940088592 immunologic factor Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000002993 trophoblast Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 230000010773 Antigen Neutralization Effects 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 101000935117 Homo sapiens Voltage-dependent P/Q-type calcium channel subunit alpha-1A Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000426 Microplastic Polymers 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 101001031591 Mus musculus Heart- and neural crest derivatives-expressed protein 2 Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000036758 Postinfectious cerebellitis Diseases 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102100025330 Voltage-dependent P/Q-type calcium channel subunit alpha-1A Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004015 abortifacient agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000919 anti-host Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical class OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 201000001383 blood group incompatibility Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000009593 intrauterine fetal growth Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000035773 mitosis phase Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 108010067933 oncofetal fibronectin Proteins 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210108746.5A CN102657876B (zh) | 2004-02-20 | 2004-02-20 | 免疫性习惯性流产的药物治疗及检测方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210108746.5A CN102657876B (zh) | 2004-02-20 | 2004-02-20 | 免疫性习惯性流产的药物治疗及检测方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004800299183A Division CN1867342A (zh) | 2004-02-20 | 2004-02-20 | 反复自然流产的治疗药物及治疗方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102657876A CN102657876A (zh) | 2012-09-12 |
| CN102657876B true CN102657876B (zh) | 2014-07-30 |
Family
ID=46767540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210108746.5A Expired - Lifetime CN102657876B (zh) | 2004-02-20 | 2004-02-20 | 免疫性习惯性流产的药物治疗及检测方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102657876B (pt) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002042769A1 (fr) * | 2000-11-22 | 2002-05-30 | Matsuura, Eiji | Procede de detection d'un anticorps anti-laminine-1 et sa mise en application |
-
2004
- 2004-02-20 CN CN201210108746.5A patent/CN102657876B/zh not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002042769A1 (fr) * | 2000-11-22 | 2002-05-30 | Matsuura, Eiji | Procede de detection d'un anticorps anti-laminine-1 et sa mise en application |
Non-Patent Citations (7)
| Title |
|---|
| Alberto R，et al.Isolation and characterization of cDNA clones for humanandbovine fibronectins.《Biochemistry》.1983,第80卷摘要，第3220页左手栏第10行-右手栏第17行和附图3. * |
| Fibronectin Fragments and Their Role in Inflammatory Arthritis;Maria-Louise Barilla et al;《Seminars in Arthritis and Rheumatism》;20000228;第29卷(第4期);摘要，第253页第6-19行 * |
| Kano, Takashi.The incidence of endometriosis and adenomyosis in Patientswith habitual abortin in relation to immunological abnormalities.《 Nippon Funin Gakkai Zasshi》.1997,第42卷(第2期),113-118. |
| Maria-Louise Barilla et al.Fibronectin Fragments and Their Role in Inflammatory Arthritis.《Seminars in Arthritis and Rheumatism》.2000,第29卷(第4期),摘要，第253页第6-19行. |
| Raphael B.et al..Successful treatment of immunologicabortion with low-dose intravenous immunoglobulin.《FERTILITY AND STERILITY7》.2000,第73卷(第3期),536-540. |
| Successful treatment of immunologicabortion with low-dose intravenous immunoglobulin;Raphael B.et al.;《FERTILITY AND STERILITY7》;20000331;第73卷(第3期);536-540 * |
| The incidence of endometriosis and adenomyosis in Patientswith habitual abortin in relation to immunological abnormalities;Kano, Takashi;《 Nippon Funin Gakkai Zasshi》;19971231;第42卷(第2期);113-118 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102657876A (zh) | 2012-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105769916B (zh) | 间充质干细胞来源外泌体在制备治疗子痫前期药物或者制剂中的应用 | |
| Seigler et al. | Embryonic development of human transplantation antigens | |
| Bourne et al. | Normal fertilization and embryo development by intracytoplasmic sperm injection of round-headed acrosomeless sperm | |
| Wang et al. | Th17/Treg‑cell balance in the peripheral blood of pregnant females with a history of recurrent spontaneous abortion receiving progesterone or cyclosporine A | |
| Chen et al. | Clinical observation of lymphocyte active immunotherapy in 380 patients with unexplained recurrent spontaneous abortion | |
| EP3194420B3 (en) | Identifying status of male fertility by determining sperm capacitation | |
| He et al. | Impaired Gal-9 dysregulates the PBMC-induced Th1/Th2 imbalance in abortion-prone matings | |
| US20180116956A1 (en) | Composition for use in treating celiac disease | |
| WO2012083884A1 (zh) | 红色诺卡氏菌细胞壁骨架增强树突状细胞功能的方法 | |
| CN102657876B (zh) | 免疫性习惯性流产的药物治疗及检测方法 | |
| CN102657877B (zh) | 免疫性习惯性流产的检查及监测方法 | |
| JPS59193829A (ja) | 特発性流産の治療用薬剤及び治療方法 | |
| Goldstein | The cross reactions of antisera prepared against four human cell strains in continuous tissue culture | |
| Ikeda et al. | Inflammation related to high-mobility group box-1 in endometrial ovarian cyst | |
| CN100504388C (zh) | 免疫性反复自然流产的诊断方法和治疗监测方法 | |
| Zammarchi et al. | Valacyclovir for prevention and treatment of fetal CMV infection: inclusion in the Law 648/96 list and launch of the Italian multicentre observational prospective study “MEGAL-ITALI” | |
| Sigman | Assisted reproductive techniques and male infertility | |
| CN111001016B (zh) | 一种vha抑制dr5在缺氧下精子生成减少的检测方法 | |
| RU2657429C2 (ru) | Способ прогнозирования задержки формирования плаценты и развития эмбриона при обострении цитомегаловирусной инфекции, подавляющей активность сосудисто-эндотелиального фактора и развития эмбриона | |
| CN1867342A (zh) | 反复自然流产的治疗药物及治疗方法 | |
| Shulman et al. | ANTIBODIES TO SPERMATOZOA | |
| US11396642B2 (en) | Tumour immunogen, preparation method therefor, and application | |
| Daboubi | Anticardiolipin antibodies in women with recurrent abortion | |
| Ding et al. | Potential Therapeutic Options for Premature Ovarian Insufficiency: Experimental and Clinical Evidence | |
| Nisell et al. | Assessment of fetal fibronectin in cervical secretion in cases of equivocal rupture of the membranes at term |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20140730 |
|
| CX01 | Expiry of patent term |